Name

Acalabrutinib

Alternate Names

Calquence

Abbreviations

None

Category

Chemotherapy

Subcategory

kinase inhibitor

NSC Number

None

Primary Site

None

Histology

Mantle cell lymphoma

Remarks

October 31, 2017: FDA has granted accelerated approval to Calquence (Acalabrutinib, previously known as ACP-196), a kinase inhibitor, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
November 21, 2019 FDA approved acalabrutinib (CALQUENCE) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Coding

This drug should be coded
Glossary